RxDoctor Payments Data

David Oelberg, MD

Pulmonary Disease · Danbury, CTNPI 1932134400

Payments from drug & device makers

$8,000in general payments, 2019–2025

Across 23 payments — averaging $347.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$8K
  • GSK$181
  • Harmony Biosciences LLC$75
  • Regeneron Healthcare Solutions, Inc.$60
  • Novartis$57

What the payments were for

  • Food & beverage$31384%
  • Education$6016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,000 in reported general payments places this provider in the 70th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$176,446
Medicare patients
1,026
Services billed
2,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate34$411,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter409$320,988
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr186$112,929
Breztri AerosphereBudesonide/Glycopyr/Formoterol103$70,007
Breo ElliptaFluticasone/Vilanterol133$66,871
Dupixent PenDupilumab17$63,534
NucalaMepolizumab15$53,701
Spiriva RespimatTiotropium Bromide36$36,604
Incruse ElliptaUmeclidinium Bromide93$36,454
Spiriva HandihalerTiotropium Bromide28$18,524
SymbicortBudesonide/Formoterol Fumarate55$16,800
Advair HfaFluticasone Propion/Salmeterol35$16,631
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$15,620
Arnuity ElliptaFluticasone Furoate31$10,952
AirsupraAlbuterol Sulfate/Budesonide19$10,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta$181$601,896867 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$7,628$463,370102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →